Cryptococcal antigen (CrAg) screening and targeted preemptive fluconazole in antiretroviral-naive human immunodeficiency virus-infected adults with CD4 cell counts <100/μL seems promising as a strategy to reduce the burden of cryptococcal meningitis (CM). We searched MEDLINE, EMBASE, and Web of Science and used random-effect meta-analysis to assess the prevalence of blood CrAg positivity (31 studies; 35 644 participants) and asymptomatic CM in CrAg-positive participants and the incidence of CM and the all-cause mortality rate in screened participants. The pooled prevalence of blood CrAg-positivity was 6% (95% confidence interval [CI], 5%-7%), and the prevalence of asymptomatic CM in CrAg-positive participants was 33% (95% CI, 21%-45%). The incidence of CM was 21.4% (95% CI, 11.6%-34.4%) without preemptive fluconazole and 5.7% (95% CI, 3.0%-9.7%) with preemptive fluconazole therapy initiated at 800 mg/d. In CrAg-positive participants, postscreening lumbar puncture before initiating preemptive fluconazole at 800 mg/d further reduced the incidence of CM to null and showed some survival benefits. However, the all-cause mortality rate remained significantly higher in CrAg-positive than in CrAg-negative participants (risk ratio, 2.2; 95% CI, 1.7-2.9; P < .001).
the World Health Organization (WHO) suggested routine CrAg screening in ART-naive HIV-infected adults with CD4 cell counts <100/μL, using either latex agglutination (LA) or lateral flow assay (LFA) procedures [20] (LFA easier and results obtained within 10 minutes [21] ). According to WHO advice, CrAg-positive patients without meningitis should be offered preemptive oral fluconazole at a tapering dose of 800 mg/d for 2 weeks, then 400 mg/d for 8 weeks, followed by 200 mg/d until the control CD4 cell count is >200/μL [20] . Nonetheless, this recommended dosage remains provisional because the optimal antifungal regimen for this population is not clearly established [22] .
CrAg screening with targeted preemptive fluconazole therapy seems attractive and cost-effective [23] [24] [25] [26] , but how best to implement it in overstretched, underresourced healthcare settings with high disease burdens remains a challenge. Nevertheless, it is incorporated into several national HIV care guidelines, both in LMICs (Botswana, Kenya, Mozambique, Namibia, Rwanda, South Africa, Swaziland, and Uganda) and high-income countries (United States and France) [4, 27] . Although the strategy is promising, a systematic assessment of its impact is lacking. We therefore performed a systematic review and meta-analysis to assess 4 key clinical outcomes of routine CrAg screening and targeted preemptive fluconazole therapy in ART-naive HIVinfected adults with CD4 cell counts <100/μL: the prevalence of CrAg positivity and asymptomatic CM in CrAg-positive participants and the incidence of CM and the all-cause mortality rate during follow-up in screened participants.
METHODS

Search Strategy and Study Selection
A medical information specialist (R. S.) developed a comprehensive search strategy to identify published and unpublished studies in MEDLINE, EMBASE, and Web of Science. Medical subject headings and keywords included cryptococcal antigen, cryptococcal surface polysaccharides, cryptococcal meningitis, HIV, screening, detection, latex agglutination, and lateral flow assay (Supplementary Table 1 ). To avoid missing relevant studies, we did not use methodological filters. Searches were run from January 1981 (year of first HIV case) through April 2018. References of included studies and previous reviews on the subject were screened for eligibility. Reports that cited included studies were also searched on Google Scholar. Conference proceedings of the Conference on Retroviruses and Opportunistic Infections, the International Conference on Cryptococcus and Cryptococcosis, and the International AIDS Society conference were screened from 2010 onward.
Two review authors (E. T., J. J. B.) independently screened studies by title and abstract and assessed full texts of potentially relevant studies. Discrepancies were discussed and when consensus was not reached, study inclusion was further discussed with a third author (J. F. C.). Study selection was done using Rayyan's online application for systematic reviews (http://rayyan.qcri.org).
We included cross-sectional studies, randomized controlled trials (RCTs), and cohort studies (retrospective and prospective) in which study participants were screened for CrAg using LA or LFA procedures. Case-control studies and case reports were excluded. Study participants had to be HIV-infected adults (aged >18 years) presenting to HIV-care programs with CD4 cell counts <100/μL, naive to ART and with no symptoms suggestive of CM, in whom serum CrAg screening was done before ART initiation. There was no country restriction. Only studies published in English, French, or Spanish were included.
In this review, the main intervention of interest was preemptive fluconazole therapy in CrAg-positive patients. However, to the best of our knowledge, there is no RCT evaluating the effectiveness of this intervention. A placebo-controlled trial would be unethical because there is enough clinical evidence to suggest that fluconazole therapy may reduce the risk of CM in severely immunosuppressed HIV-infected patients [16] . Consequently, in the present review, the impact of this intervention was evaluated based on observational studies.
Our clinical outcomes of interest were: (1) the prevalence of blood (serum/plasma) CrAg positivity in screened participants, (2) the prevalence of asymptomatic CM (ascertained by positive fungal culture and/or Indian ink staining and/or CrAg in cerebrospinal fluid [CSF]) in blood CrAg-positive patients, (3) the incidence of CM during follow-up, and (4) the all-cause mortality rate during follow-up.
Data Extraction and Quality Assessment
For each study, we extracted the following: (1) study characteristics: first author, publication year, design (RCT, cohort, cross-sectional), and country; (2) participant characteristics: total number, proportion of ART naive, and number with CD4 cell counts <100/μL; (3) CrAg screening test procedure (LA or LFA); (4) CrAg screening outcome: number screened, number and proportion CrAg positive; (5) interventions offered to CrAg-positive patients: lumbar puncture (No. with confirmed asymptomatic CM), preemptive fluconazole therapy (offered or not, No. of participants offered fluconazole, initial dose offered, duration), and ART (median time to initiation, if available); and (6) clinical outcomes within follow-up: incidence of CM (No. and proportion in CrAg-positive and CrAg-negative participants), all-cause mortality data (No. and proportion in CrAgpositive and CrAg-negative participants), and number lost to follow-up within each group, if reported.
We assessed the risk of bias only in studies in which screened patients were subsequently followed up. For this, we adapted a quality assessment tool (Supplementary Table 2 ) based on the Joanna Briggs Institute checklist for cohort studies [28] . The main components of the review question considered were study population (HIV-infected adults with CD4 cell counts <100/ μL), exposure (CrAg status and the method used to determine it), intervention (targeted preemptive fluconazole therapy or not, ART to screened patients), and the outcomes of interest during follow-up (incidence of CM and all-cause mortality data). For each study, we assessed patient selection bias, treatment allocation bias, outcome assessment bias, and completeness of outcome data bias. Where insufficient information was reported, we contacted study authors for clarification.
Data Analysis
Data were pooled using standard random-effects meta-analysis for proportions and using the Freeman-Tukey double arcsine transformation and the metaprop command [29] in Stata 15.0 software (StataCorp) to estimate the prevalence of CrAg positivity in screened participants and the prevalence of asymptomatic CM in CrAg-positive participants, and these values were reported with their 95% confidence intervals (CIs).
In studies in which screened participants were subsequently followed up, random-effects models were used in Review Manager (RevMan) software, version 5.3 [30] , to estimate the incidence of CM and the all-cause mortality rate during follow-up as well as risk ratios comparing CrAg-positive with CrAg-negative participants. This analysis was stratified by the type of interventions offered to CrAg-positive participants (ie, no preemptive fluconazole, preemptive fluconazole initiated at <800 or 800 mg/d or initiated at 800 mg/d after postscreening lumbar puncture).
Heterogeneity was evaluated graphically by observing forest plots and by calculating I 2 statistics. Additional stratified analysis was performed to explore heterogeneity when I 2 was >50%.
The protocol was registered in the PROSPERO international prospective register of systematic reviews (registration No. CRD42018087608).
RESULTS
The electronic search performed on 20 April 2018 identified 2115 citations (314 duplicates). Based on title and abstract screening, 1741 citations were excluded ( Figure 1 ). On further assessment of 60 citations, 29 more were excluded. A total of 31 studies were included for estimating the prevalence of CrAg positivity [14, 22, 23, 26, , of which 10 were used to evaluate the prevalence of asymptomatic CM in CrAg-positive participants [31, 33, 40, 41, 45, 48, 50, 51, 55, 57] , 4 to evaluate the CM incidence and allcause mortality rates in the context of no fluconazole preemptive therapy [14, 32, 35, 49] , and 20 to evaluate the CM incidence and/or all-cause mortality rates in the context of preemptive fluconazole therapy [14, 22, 23, 32, 33, 35, 39-45, 48-51, 53, 55, 56] . The quality of included studies is summarized in the supplementary text and Supplementary Figure 1 .
Prevalence of Blood CrAg Positivity and Asymptomatic CM in CrAgpositive Participants
Thirty-one studies from 22 countries (67.7% sub-Saharan African) were included [14, 22, 23, 26, of which 22 (71%) were cohorts, 3 (9.7%) were RCTs, and 6 (19.4%) were cross-sectional (Table 1) . In these studies, 38 383 participants underwent CrAg screening irrespective of CD4 cell count, of whom 35 644 (92.9%) had CD4 cell counts <100/μL (our target population). Screening was done with LFA in 20 studies (64.5%) and with LA in the rest. Screening was performed in real time on fresh serum samples in 20 studies (64.5%) and retrospectively on stored serum samples in 11 (35.5%). In participants with CD4 cell counts >100/ μL, the median prevalence of CrAg positivity was 2% (interquartile range, 1%-3%). In those with CD4 cell counts <100/μL, CrAg positivity ranged from 0% to 21%, and the pooled prevalence was 6% (95% CI, 5%-7%; I 2 = 89.3%) (Figure 2 Figures 2 and 3) . After CrAg screening, lumbar puncture was offered to CrAgpositive participants (who presented no symptoms of CM) in 10 studies [31, 33, 40, 41, 45, 48, 50, 51, 55, 57] . Among the 403 participants eligible for lumbar puncture, 276 (68.5%) accepted, and the pooled prevalence of confirmed asymptomatic CM in CrAg-positive participants was 33% (95% CI, 21%-45%; I 2 = 76.1%) (Figure 3 ).
Incidence of CM
During the median follow-up of 1 year (interquartile range, 0.5-1 year), when CrAg-positive participants were not offered preemptive fluconazole, the incidence of CM was 21.4% (95% CI, 11.6%-34.4%) vs 0.4% (95% CI, 0.1%-1%) in CrAg-negative participants (Table 2 and Figure 4A ). When preemptive fluconazole was offered to CrAg-positive participants, stratifying by initial dose, dosages <800 mg/d were associated with more incident cases of CM than 800 mg/d: 9.1% (95% CI, 2.5%-21.7%) versus 5.7% (95% CI, 3.0%-9.7%), Figure 4B . In these analyses, incidence was consistently <1% in CrAg-negative participants (Table 2) . Moreover, performing lumbar puncture in CrAgpositive participants to exclude those with confirmed asymptomatic CM before initiating preemptive fluconazole at 800 mg/d significantly reduced the incidence of CM to levels similar to those in CrAg-negative participants: 0% (95% CI, 0%-0.8%) and 0.4% (95% CI, 0%-1%) (P = .12), respectively and this effect was independent of the CrAg test used (Supplementary Figure 4. 1).
All-cause Mortality Rates
After CrAg screening, when no preemptive fluconazole was offered to CrAg-positive participants, the all-cause mortality rate during follow-up was significantly higher than in CrAgnegative participants: 39.7% (95% CI, 28.8%-51.5%) versus 13.9% (95% CI, 11.8%-16.2%), respectively (Table 3 and Figure 5A ). Offering preemptive fluconazole at 800 mg/d was associated with decreased mortality risk compared with no fluconazole in CrAg-positive participants: 17.4% Nevertheless, the all-cause mortality rate remained significantly higher in CrAg-positive than in CrAg-negative participants, even after exclusion of CrAg-positive participants with asymptomatic CM before initiation of fluconazole treatment at 800 mg/d (risk ratio, 2.2; 95% CI, 1.7%-2.9%; P < .001) ( Table 3 and Figure 5C ), independent of the CrAg test used (Supplementary Figure 4. 2). 
DISCUSSION
Main Findings
This systematic review and meta-analysis shows that (1) the prevalence of CrAg positivity in asymptomatic HIV-infected patients with CD4 cell counts <100/μL is about 6% [4, 58] ; (2) the prevalence of asymptomatic CM among CrAg-positive patients is approximately 30%; (3) the incidence of CM in these patients drops from about 20% without preemptive fluconazole to 5% with preemptive fluconazole initiated at 800 mg/d; and (4) initiating preemptive fluconazole at 800 mg/d after excluding patients with asymptomatic CM reduced the overall mortality rate in CrAg-positive patients from about 40% to about 20%, but these patients still had >2-fold the risk of death in CrAgnegative patients.
Implications for Practice
Our findings show that targeted preemptive fluconazole initiated at 800 mg/d may reduce the incidence of CM from about 20% to about 5%, strong evidence of its effectiveness. Furthermore, when CrAg-positive patients were offered postscreening lumbar puncture, the incidence of CM was reduced even further to <1%, comparable to the incidence observed in CrAg-negative patients. This supports systematically offering lumbar puncture to those who are CrAg positive to prevent clinically asymptomatic patients with CSF evidence of meningitis from receiving suboptimal induction antifungal treatment with fluconazole monotherapy, which is known to be less effective in CM even at the highest dosages [59, 60] . In other words, the observed incident CM cases during follow-up, despite preemptive fluconazole therapy, might result from insufficient treatment and unmasking secondary to immune reconstitution inflammatory syndrome [61] . We therefore suggest that the objective is not only to identify CrAg-positive patients, but also to identify those among them who have asymptomatic CM. Patients with asymptomatic CM should be treated with the recommended induction antifungal combination therapy-1 week of amphotericin B plus flucytosine or oral high-dose fluconazole plus flucytosine [62] whereas fluconazole preemptive therapy should be restricted to those without CSF evidence of CM.
In studies reporting the experience of routine CrAg screening and targeted fluconazole therapy in LMICs, we found little heterogeneity, suggesting similarities across these studies in the overall implementation of the CrAg screen-and-treat strategy: tests used, classification of patients as CrAg positive or negative, fluconazole for CrAg-positive patients, postscreening ART initiation, and follow-up and reporting of ascertained CM cases over time. However, there was much variability in how fluconazole was offered to CrAg-positive patients, in terms of dosage and duration. Few studies provided fluconazole at the WHOsuggested tapering dose and duration [40, 42, 43, 45, 48, [51] [52] [53] 55] . In some studies, fluconazole was initiated at 800 mg/d and provided for 4 weeks only [41] or for 2 weeks followed by 400 mg/d for another 2 weeks and cessation of therapy [22] ; these short courses seemed to be due to local realities of insufficient fluconazole availability. This shows that for targeted preemptive therapy to be effective as a preventive strategy for CM, readily available and sustainable fluconazole is a prerequisite, especially because CrAg point-of-care tests are becoming more available [21, 63] and accepted by clinicians and patients.
Implications for Research
Given that most studies show moderate lumbar puncture feasibility and acceptance (68.5%), there is critical need for more acceptable methods for identifying patients with asymptomatic CM among those who are CrAg positive. With existing evidence of association between serum CrAg titers and asymptomatic CM [43, 45, 55, 57, 64] , systematic per-screening CrAg quantification can be done, and a threshold defined beyond which patients could be considered for recommended inductive combination antifungal therapy [62] . Available evidence suggests that such a threshold is a titer of about 1:160 [45, 55, 57, 64] and a recent Ugandan study [43] showed a strong association between this titer level and incident CM within weeks of ART initiation. Future research should aim at evaluating whether semiquantitative point-of-care CrAg tests [55, 63] capable of identifying patients with high titers [65] would increase the effectiveness of preemptive therapy. With regard to the effect of targeted preemptive therapy on all-cause mortality rates, we found some evidence that initiating fluconazole at 800 mg/d in CrAg-positive patients exempt of asymptomatic CM may have some benefits for mortality during the first year of ART initiation. However, mortality rates were still significantly higher than in CrAg-negative patients, suggesting the existence of poorly understood non-CM CrAg status-related mortality predispositions worthy of further exploration. Perhaps, after ART initiation, CrAg positivity may affect immune response to other opportunistic infections leading to death. Further research could therefore focus on the quality of immune responses after ART initiation, comparing CrAg-positive with CrAg-negative patients.
Study Limitations
Our study has some limitations. The effect of preemptive fluconazole on CM incidence and all-cause mortality rates in CrAgpositive patients was indirectly evaluated because most of the included studies were observational with very few RCTs. Even among the included RCTs, none was randomized to compare preemptive fluconazole to no fluconazole or to an alternative preemptive therapy in CrAg-positive patients. Consequently, we report only indirect evidence for the effectiveness of the WHO CrAg screen-and-treat strategy. Furthermore, not all studies evaluated our predefined main outcomes of interest and this resulted in variable denominators (No. of studies and No. of participants) across the outcomes. Moreover, the data were scarce for several outcomes, with blank cells leading to unstable estimates and wide CIs. We acknowledge that effects on incidental CM cases and mortality rates during follow-up would have been better assessed through more reliable survival methods that account for censoring, but these data were not available for analysis. None of the studies addressed CrAg screening and preemptive therapy in ART-experienced patients, although growing evidence suggests a considerable proportion of patients with advanced HIV infection due to failing ART.
CONCLUSIONS
In conclusion, offering fluconazole preemptive therapy at presently recommended doses to CrAg-positive patients, compared with no fluconazole, substantially reduces the risk of incident CM and may have survival benefits. The high prevalence of asymptomatic CM in CrAg-positive patients, together with low uptake of lumbar puncture, justifies the development of reliable point-of-care tests capable of identifying, at the point of screening, CrAg-positive patients at higher risk of underlying asymptomatic CM. The availability of sustainable fluconazole in ART programs is essential for effective preemptive strategies.
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